Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P797 | ISIN: US65487U1088 | Ticker-Symbol:
NASDAQ
24.04.25
15:34 Uhr
2,170 US-Dollar
-0,005
-0,23 %
1-Jahres-Chart
NKARTA INC Chart 1 Jahr
5-Tage-Chart
NKARTA INC 5-Tage-Chart

Aktuelle News zur NKARTA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.03.Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?4
27.03.Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy4
NKARTA Aktie jetzt für 0€ handeln
27.03.Stifel cuts Nkarta stock price target to $14, maintains buy rating3
27.03.H.C. Wainwright maintains Buy on Nkarta stock with $18 target3
27.03.Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program3
27.03.Stifel cuts NKTX stock price target to $14, maintains buy rating2
26.03.Nkarta GAAP EPS of -$0.35 beats by $0.063
26.03.Nkarta, Inc. - 10-K, Annual Report1
26.03.Nkarta, Inc. - 8-K, Current Report2
26.03.Nkarta, Inc.: Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights349Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune...
► Artikel lesen
02.01.Nkarta, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
05.12.24Nkarta, Inc.: Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-212
08.11.24Nkarta ending development of asset for lymphoma2
08.11.24Nkarta continues pivot to autoimmune by shelving lymphoma program for CAR NK candidate3
07.11.24Nkarta, Inc. - 10-Q, Quarterly Report1
07.11.24Nkarta, Inc. - 8-K, Current Report-
27.06.24Nkarta, Inc.: Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications172Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019...
► Artikel lesen
09.05.24Nkarta, Inc.: Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights555Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1